AiCuris expands its Management with Prof. Dr. Hubert Trübel joining as Chief Medical Officer and the Appointment of Dr. Tamara Pfaff, Head of Preclinical Development, to the Management Team

• Prof. Hubert Trübel succeeds Dr. Manickam Rangaraju as CMO and Head of Clinical Development
• As CMO, Prof. Trübel will be responsible for the entire clinical pipeline including AiCuris' main programs, Pritelivir, planned to enter a pivotal Phase 3 trial in 2021 for the treatment of acyclovir-resistant HSV infections and AIC649, a broad-acting immunmodulator currently being tested against SARS-CoV-2
• In her new position, Dr. Tamara Pfaff will represent all preclinical activities within the management team and strengthen these activities in AiCuris' R&D organisation

WUPPERTAL, Germany, March 30, 2021 - AiCuris, a leading company in the discovery and development of drugs against infectious diseases, today announced that Prof. Hubert Trübel joined AiCuris as Head of Clinical Development and Chief Medical Officer. In addition, the Head of Preclinical Development, Dr. Tamara Pfaff, was also appointed to the management team effective April 1, 2021.

Prof. Trübel brings with him more than 20 years of experience in academia and the pharmaceutical industry with an extensive track record in the management of international clinical development across a variety of treatment areas. As CMO, he will be responsible for the entire AiCuris clinical development pipeline including the Company's main programs Pritelivir and AIC649. Pritelivir is planned to enter a pivotal Phase 3 trial in 2021 for the treatment of immunocompromised patients whose HSV infections have become resistant to acyclovir. With AIC649 the focus will be on the exploitation of the full potential of this immune modulator, currently being investigated for the treatment of SARS-CoV-2.

Prof. Trübel succeeds Dr. Manickam Rangaraju, who plans to retire after serving many years as AiCuris' CMO. Based on his deep and sound knowledge in anti-infective indications, Dr. Rangaraju was instrumental over the years in building up and supporting our successful development pipeline. We are glad that Dr. Rangaraju will continue to serve as AiCuris' Senior Clinical Consultant further supporting the Company with his decades of R&D experience in the field of anti-infectives.

In addition, AiCuris appoints Dr. Tamara Pfaff, Head of Preclinical Development to the management team. In her role, she will be responsible for all preclinical development activities of current AiCuris assets including the due diligence of future in-licensing opportunities.

"We are excited to welcome Prof. Trübel to AiCuris. Our team will benefit from his extensive experience and experties in clinical stage R&D to successfully drive our innovative development projects in the future. The months to come will be extremely important for AiCuris with two important clinical trials about to start and the continued expansion of our pipeline in the antiviral and antibiotics fields. We are pleased that in Prof. Trübel we have found the ideal candidate to build on the success of Dr. Rangaraju whom we sincerely thank for his contributions over the past years," said Dr. Holger Zimmermann, CEO of AiCuris. "At the same time I would like to welcome Dr. Pfaff to the management team. With her many years of experience in toxicology, preclinical drug safety and development assessment, she will especially strengthen the focus of our preclinical development activities and provide excellent support to our strategy to further develop and expand the Company's promising pipeline in virology and bacteriology. With this change and addition we feel that we are very well set up for the preclinical and clinical work ahead of us"

"I am thrilled to join the AiCuris team during these exciting times," said Prof. Dr. Hubert Trübel, CMO of AiCuris. "The Company has its first drug already on the market and with the second compound, Pritelivir, to enter Phase 3 development and AIC649 to start shortly clinical development in the prevention of COVID-19 as well as other upcoming infections with pandemic potential, it is facing a number of important clinical developments ahead. I look forward to working with the AiCuris team to drive the clinical development of this promising portfolio to address various unmet needs in the antiinfective field."

Before coming to AiCuris, Prof. Trübel was Senior Vice President & Head of "Translational Medicine" at Bayer Pharma Research & Development. Previosly, amongst others he held various leading positions throughout his 12 year career at Bayer AG, including Vice President & Head of "Experimental Medicine Cardiovascular/Hematolgy." Prof. Trübel habilitated in 2006 at the private University of Witten/Herdecke, where he also was member of the faculty board from 2004 to 2008. He is a member of the German Socienty of Cardiology (DGK) and of the Ethics Committee at the University of Witten/Herdecke. Prof. Trübel earened his M.D. from the University of Mainz, Germany and an MBA from the University of Illinois, U.S.A.

Dr. Pfaff joined AiCuris in 2010 as Head of Preclinical Drug Safety and steadily increased her responsibilities. She became Senior Director in 2018 and was responsible for all preclinical safety aspects of the AiCuris portfolio. In 2020, she became Head of Preclinical Development. Dr. Pfaff started her industrial career in 2004 as Head of Laboratory Preclinical Development in the Global Research and Development department of Gruenenthal GmbH and was promoted to International Preclinical Project Leader in 2009. Dr. Pfaff is a trained veterinarian and in addition holds a master's degree in applied toxicology. She is a German board certified pathologist and recognized as an Eurotox-registered toxicologist. Dr. Pfaff studied at the Universities of Gießen and Surrey, Guildford (UK).

About AiCuris

AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs targeting infectious diseases. SANTO Holding is the Company's majority investor. PREVYMIS(R) (Letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor acting via a novel mechanism of action, was licensed to MSD in 2012 and is approved in the EU, the USA, Japan and other parts of the world for use in bone marrow transplants for the prevention of HCMV infections in adults who receive an allogeneic hematopoietic stem cell transplant. The Company is developing drugs for the treatment of viruses such as human CMV, herpes simplex virus (HSV), hepatitis B virus (HBV), and adenoviruses. In the field of antibacterials, AiCuris seeks to develop innovative treatment options for life-threatening, multidrug-resistant, hospital-treated pathogens.

For more information, please visit www.aicuris.com.
Follow us on LinkedIn.

Contacts: